Shanghai Fosun Pharmaceutical Group Co Ltd (600196) — Capital Reinvestment Ratio
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has a Capital Reinvestment Ratio of 0.53x as of December 2025, meaning it reinvests 1% of its operating cash flow (CN¥2.40 Billion) in capital expenditures (CN¥1.28 Billion). See Shanghai Fosun Pharmaceutical Group Co L (600196) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Shanghai Fosun Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks Shanghai Fosun Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 28 annual periods.
Annual Capital Reinvestment Ratio for Shanghai Fosun Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for Shanghai Fosun Pharmaceutical Group Co Ltd from 1998 to 2025. For live market cap and broader valuation context, see Shanghai Fosun Pharmaceutical Group Co L (600196) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.74x | CN¥6.01 Billion | CN¥4.45 Billion | ▼ -24.8% |
| 2024 | 0.99x | CN¥4.48 Billion | CN¥4.41 Billion | ▼ -19.5% |
| 2023 | 1.22x | CN¥4.36 Billion | CN¥5.34 Billion | ▼ -12.4% |
| 2022 | 1.40x | CN¥4.22 Billion | CN¥5.89 Billion | ▲ +10.9% |
| 2021 | 1.26x | CN¥3.95 Billion | CN¥4.97 Billion | ▼ -26.8% |
| 2020 | 1.72x | CN¥2.58 Billion | CN¥4.44 Billion | ▲ +39.9% |
| 2019 | 1.23x | CN¥3.22 Billion | CN¥3.96 Billion | ▲ +14.2% |
| 2018 | 1.08x | CN¥2.95 Billion | CN¥3.17 Billion | ▲ +27.9% |
| 2017 | 0.84x | CN¥2.58 Billion | CN¥2.17 Billion | ▼ -7.6% |
| 2016 | 0.91x | CN¥2.11 Billion | CN¥1.92 Billion | ▲ +19.5% |
| 2015 | 0.76x | CN¥1.62 Billion | CN¥1.24 Billion | ▼ -18.3% |
| 2014 | 0.93x | CN¥1.20 Billion | CN¥1.12 Billion | ▼ -9.3% |
| 2013 | 1.03x | CN¥1.01 Billion | CN¥1.04 Billion | ▼ -41.0% |
| 2012 | 1.74x | CN¥665.52 Million | CN¥1.16 Billion | ▼ -30.7% |
| 2011 | 2.52x | CN¥316.65 Million | CN¥796.83 Million | ▲ +50.9% |
| 2010 | 1.67x | CN¥203.36 Million | CN¥339.17 Million | ▲ +25.5% |
| 2009 | 1.33x | CN¥261.87 Million | CN¥348.07 Million | ▲ +47.1% |
| 2008 | 0.90x | CN¥233.04 Million | CN¥210.63 Million | ▼ -43.3% |
| 2007 | 1.59x | CN¥131.48 Million | CN¥209.71 Million | ▲ +10.6% |
| 2006 | 1.44x | CN¥184.91 Million | CN¥266.61 Million | ▲ +22.0% |
| 2005 | 1.18x | CN¥188.35 Million | CN¥222.60 Million | ▲ +18.2% |
| 2004 | 1.00x | CN¥205.10 Million | CN¥205.02 Million | ▼ -43.2% |
| 2003 | 1.76x | CN¥150.14 Million | CN¥264.05 Million | ▲ +29.2% |
| 2002 | 1.36x | CN¥102.47 Million | CN¥139.52 Million | ▼ -34.4% |
| 2001 | 2.08x | CN¥68.15 Million | CN¥141.51 Million | ▲ +127.0% |
| 2000 | 0.91x | CN¥138.43 Million | CN¥126.63 Million | ▼ -55.2% |
| 1999 | 2.04x | CN¥38.20 Million | CN¥77.99 Million | ▲ +160.1% |
| 1998 | 0.79x | CN¥66.55 Million | CN¥52.25 Million | — |